Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

20.00 

0.00 0.0%

as of Jan 16 '20

52 Week Range:

6.79 20.45


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts. As of January 16, 2020, ArQule, Inc. operates as a subsidiary of Merck Sharp & Dohme Corp.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 0.98
0.26
-0.32
0.46
1.30
1.05
0.69
0.50
0.42
0.07
0.80
growth rate -73.5% -100.0% 100.0% 182.6% -19.2% -34.3% -27.5% -16.0% -83.3% 1,042.9%
Earnings BIT -50.86
-35.59
-30.68
-10.76
-10.87
-24.60
-23.17
-14.15
-22.90
-27.02
-13.70
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE -3.30
-5.50
-7.20
-29.40
-30.60
-2.65
-2.65
-2.65
-2.65
-2.70
-2.70
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROA -28.54
-18.72
-23.11
-10.45
-8.65
-21.17
-28.95
-26.64
-62.77
-71.86
-19.90
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROE -77.36
-131.40
206.90
-141.91
-19.63
-34.73
-46.24
-39.51
-85.96
-154.26
-33.24
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROIC -44.81
-48.93
-119.07
-19.78
-34.57
-46.71
-39.80
-86.63
-83.25
-24.56
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 1.72
1.88
1.74
1.48
2.99
3.47
3.34
3.65
3.67
4.98
7.28
growth rate 9.3% -7.5% -14.9% 102.0% 16.1% -3.8% 9.3% 0.6% 35.7% 46.2%
Quick Ratio 1.71
1.85
1.72
1.39
2.97
3.43
3.24
3.58
3.58
4.92
7.22
growth rate 8.2% -7.0% -19.2% 113.7% 15.5% -5.5% 10.5% 0.0% 37.4% 46.8%
Leverage 4.93
14.90
3.94
1.66
1.62
1.56
1.37
1.37
3.45
1.35
growth rate 202.2% -48.6% -57.9% -2.4% -3.7% -12.2% 0.0% 151.8% -60.9%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 0.00
0.00
0.00
0.00
0.00
5.98
growth rate
Acct.Payable 11.93
10.16
8.47
0.26
0.19
0.71
0.54
1.33
growth rate -14.8% -16.7% -96.9% -28.2% 281.7% -24.4% 147.5%
Cur.Assets 142.70
157.20
81.80
72.19
79.62
75.64
61.10
39.49
31.95
48.58
106.40
growth rate 10.2% -48.0% -11.8% 10.3% -5.0% -19.2% -35.4% -19.1% 52.1% 119.0%
Total Assets 214.20
171.90
88.90
117.05
134.19
98.18
63.39
40.00
32.38
48.90
106.68
growth rate -19.8% -48.3% 31.7% 14.6% -26.8% -35.4% -36.9% -19.1% 51.0% 118.1%
Cash 141.90
36.60
20.50
11.10
14.33
15.58
12.53
13.98
15.27
20.23
19.24
growth rate -74.2% -44.0% -45.9% 29.1% 8.7% -19.6% 11.6% 9.2% 32.5% -4.9%
Inventory 0.00 0.00 0.00 0.00 0.00
growth rate
Cur.Liabilities 83.00
83.60
46.90
48.89
26.65
21.75
18.28
10.83
8.70
9.76
14.62
growth rate 0.7% -43.9% 4.2% -45.5% -18.4% -16.0% -40.8% -19.6% 12.2% 49.8%
Liabilities 170.70
160.30
103.40
87.32
53.16
37.55
22.85
10.83
8.70
24.37
27.71
growth rate -6.1% -35.5% -15.6% -39.1% -29.4% -39.2% -52.6% -19.6% 180.1% 13.7%
LT Debt 0.00
0.00
0.00
0.00
0.00
14.61
13.09
growth rate -10.4%
Equity 43.50
11.50
-14.56
29.73
81.03
60.63
40.55
29.18
23.68
14.18
78.97
growth rate -73.6% -100.0% 100.0% 172.6% -25.2% -33.1% -28.0% -18.9% -40.1% 456.9%
Common Shares 44.00
44.00
45.00
53.00
60.00
62.00
63.00
63.00
70.00
75.00
99.00
growth rate 0.0% 2.3% 17.8% 13.2% 3.3% 1.6% 0.0% 11.1% 7.1% 32.0%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 3.40
0.70
0.40
0.59
0.12
0.00
0.32
0.32
0.02
growth rate -79.4% -42.9% 48.5% -80.3% -100.0% 0.0% -95.2%
Cash Dividends 0.00 0.00 0.00 0.00 0.00
growth rate
Cash From OA 27.50
-41.76
-34.82
-23.74
-34.20
-31.78
-22.16
-22.94
-25.18
-12.98
growth rate -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF per Share 0.55
-0.96
-0.78
-0.25
-0.57
-0.56
-0.52
-0.39
-0.32
-0.38
-0.13
growth rate -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 51.22
57.93
0.29
0.11
0.13
15.36
17.97
growth rate 13.1% -99.5% -63.7% 27.6% 11,359.0% 17.0%
FCF 24.00
-42.00
-35.00
-24.00
-34.00
-34.00
-32.00
-22.00
-23.00
-25.00
-13.00
growth rate -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 14.10
25.20
29.20
47.31
36.41
15.91
11.25
11.24
4.71
25.76
growth rate 78.7% 15.9% 62.0% -23.0% -56.3% -29.3% -0.1% -58.1% 133.9%
Op.Income -52.40
-37.60
-31.30
-10.76
-10.87
-24.60
-23.17
-14.15
-22.90
-27.02
-13.70
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT -50.90
-35.60
-30.70
-10.76
-10.87
-24.60
-23.39
-13.77
-22.72
-29.20
-15.48
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income -50.90
-36.10
-30.10
-10.76
-10.87
-24.60
-23.39
-13.77
-22.72
-29.20
-15.48
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
EPS -1.16
-0.82
-0.68
-0.20
-0.18
-0.39
-0.37
-0.22
-0.33
-0.39
-0.16
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit 14.10
25.20
29.20
47.31
36.41
15.91
-11.02
-4.32
-15.33
-19.47
-2.95
growth rate 78.7% 15.9% 62.0% -23.0% -56.3% -100.0% 0.0% 0.0% 0.0% 0.0%
R&D 49.60
49.50
47.00
45.01
33.97
27.56
22.27
15.56
20.04
19.47
growth rate -0.2% -5.1% -4.2% -24.5% -18.9% -19.2% -30.1% 28.8% -2.9%

Quarterly Statements

Item Name Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Earnings BIT -5.71
-8.65
-10.40
-9.22
-11.28
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Acct.Receivable 6.40
5.98
3.30
1.45
0.87
growth rate -6.5% -44.9% -56.1% -39.7%
Acct.Payable 1.07
1.33
0.98
0.98
0.80
growth rate 24.1% -26.2% 0.2% -18.5%
Cur.Assets 107.36
106.40
96.89
182.00
128.04
growth rate -0.9% -8.9% 87.8% -29.7%
Total Assets 112.55
106.68
98.47
187.19
180.34
growth rate -5.2% -7.7% 90.1% -3.7%
Cash 16.18
19.24
17.82
108.69
42.20
growth rate 18.9% -7.3% 509.8% -61.2%
Cur.Liabilities 11.19
14.62
15.02
14.51
15.48
growth rate 30.6% 2.8% -3.4% 6.7%
Liabilities 25.45
27.71
27.39
25.58
27.22
growth rate 8.9% -1.2% -6.6% 6.4%
LT Debt 14.26
13.09
11.92
10.75
9.58
growth rate -8.2% -8.9% -9.8% -10.9%
Equity 87.10
78.97
71.09
161.62
153.13
growth rate -9.3% -10.0% 127.4% -5.3%
Common Shares 1.09
1.09
1.09
1.20
1.21
growth rate 0.0% 0.1% 10.3% 0.3%
Cash Flow Statement Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Capital Expenditures 0.28
0.28
0.28
0.15
0.05
growth rate 0.0% 0.0% -46.6% -70.0%
Cash Dividends
growth rate
Cash From OA -5.83
-5.18
-7.05
-7.98
-9.19
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock
growth rate
FCF -6.11
-5.46
-7.33
-8.13
-9.24
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Sales 4.98
2.94
1.35
0.28
0.21
growth rate -40.9% -54.3% -79.1% -26.0%
Op.Income -5.71
-8.65
-10.40
-9.22
-11.28
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -5.62
-8.49
-10.27
-9.09
-10.74
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -5.62
-8.49
-10.27
-9.09
-10.74
growth rate 0.0% 0.0% 0.0% 0.0%
EPS
growth rate
Gross Profit -2.28
-5.91
-6.10
-6.05
-8.11
growth rate 0.0% 0.0% 0.0% 0.0%
R&D
growth rate

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (7.81)

YOY Growth Grade:

F (0.00)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -2.70 -58.14 -54.05
EPS / Growth 0.0% -0.34 8.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 19.3% 27.6%
Future PE 0.00 0.01 18.39
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.